文献速递关节外科创伤骨科

全股骨占位器二期置换治疗假体周围关节感染:占位器并发症与植入物生存率

Two-Stage Exchange Using a Total Femur Spacer in the Management of Periprosthetic Joint Infection - Spacer Complications and Implant Survivorships.
PubMed 文献 · J Arthroplasty · 2023-05-02

单中心回顾性分析32例因慢性假体周围关节感染伴大量股骨骨缺损而行全股骨抗生素占位器置入的患者,中位随访46个月。占位器相关并发症发生率为34%,25%因该原因行翻修;二期再植入后无感染植入物生存率2年为85%、5年为53%,44%患者在中位40个月后截肢。

要点

  • 全股骨占位器相关并发症发生率为34%(11/32),25%因此行翻修。
  • 一期术后92%患者被认为感染已控制,84%完成二期全股骨假体再植入。
  • 二期再植入后无感染植入物生存率2年85%、5年53%,44%最终截肢。

核心结论

  • 全股骨占位器可在超过90%的病例中实现感染控制,且占位器本身的并发症发生率合理。
  • 然而,二期巨假体全股骨关节置换术后的再感染及后续截肢率约为50%。

研究设计与样本

  • 单中心回顾性分析,纳入2010年至2019年间因慢性假体周围关节感染伴大量股骨骨缺损而作为计划性二期置换的一部分置入全股骨占位器的32例患者,中位年龄67岁(范围15-93),女性18例,中位随访46个月(范围1-149)。
  • 采用Kaplan-Meier生存估计分析植入物及肢体生存率,并分析失败的潜在危险因素。

主要发现

  • 34%(11/32)患者出现占位器相关并发症,25%因此行翻修。
  • 一期术后92%患者被认为感染已控制;84%患者接受二期模块化巨假体全股骨关节置换再植入。
  • 无感染植入物生存率2年为85%,5年为53%。
  • 44%患者在中位40个月(范围2-110)后接受截肢。
  • 一期手术最常培养出凝固酶阴性葡萄球菌,而再感染时最常为多种微生物生长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic periprosthetic joint infection after revision hip and knee arthroplasties can lead to subsequent massive femoral bone loss. In these cases, resection of the residual femur and placement of an antibiotic total femoral spacer can be an option to salvage the limb. METHODS: This is a single-center retrospective analysis of 32 patients (median age 67 years; range 15-93; 18 women) who underwent placement of a total femur spacer for chronic periprosthetic joint infection with massive femoral bone loss between 2010 and 2019 as part of a planned two-stage exchange. The median follow-up period amounted to 46 months (range, 1-149). Implant and limb survival were analyzed using Kaplan-Meier survival estimates. Potential risk factors for failure were analyzed. RESULTS: There were 34% (11 of 32) of patients having a spacer-associated complication, and 25% underwent revision for this reason. After the first stage, 92% were considered infection-free. There were 84% of patients who underwent second-stage reimplantation of a total femoral arthroplasty using a modular megaprosthetic implant. Infection-free implant survival was 85% after 2 years and 53% after 5 years. There were 44% of patients who underwent amputation after a median time of 40 months (range, 2-110). Most commonly, coagulase-negative staphylococci were cultured at first-stage surgery, while polymicrobial growth was most common at reinfection. CONCLUSION: Total femur spacers can lead to infection control in over 90% of cases with a reasonable complication rate for the spacer itself. However, the reinfection and subsequent amputation rate after second-stage megaprosthetic total femoral arthroplasty is around 50%.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Theil C, Moellenbeck B, Puetzler J, et al. Two-Stage Exchange Using a Total Femur Spacer in the Management of Periprosthetic Joint Infection - Spacer Complications and Implant Survivorships. J Arthroplasty. 2023. PMID: 37142068. doi:10.1016/j.arth.2023.04.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。